Latest Conference Articles

Ravi A. Madan, MD, discusses data from a phase 2 trial of enzalutamide monotherapy in patients with biochemically recurrent prostate cancer.

Jose Mauricio Mota, MD, PhD, discusses results from the Daro-PET study, which evaluated whether short-course darolutamide increases PSMA expression in prostate cancer.

An analysis of RETAIN-1 and RETAIN-2 showed ctDNA was prognostic for metastatic recurrence in MIBC.

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Stacy Loeb, MD, discusses findings from a study evaluating microplastics in prostate cancer tissue.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

Age was correlated with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

Nathan Denlinger, DO, discusses real-world data with second-line liso-cel and axi-cel in patients with relapsed/refractory large B-cell lymphoma.

Fernando Gibran-Nunes, MD, highlights findings from a meta-analysis investigating the efficacy and safety of loncastuximab tesirine in pretreated DLBCL.

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

Peter Riedell, MD, discussed the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma.

Kenneth Jin Chang Lim, MBBS, discusses the failure of dexamethasone to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy.

Real-world data show over an 40% response rate for lifileucel TIL therapy, for previously treated advanced melanoma.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.